Abstract #1156

Predictive Value of Magnetic Resonance Spectroscopic Imaging during Anti-angiogenic Treatment in Recurrent Glioblastoma

Daniel Kim^1,2, Jorg Dietrich³, Elizabeth Gerstner^2,3, Julian He¹, Otto Rapalino¹, Yangming Ou⁴, Yi-Fen Yen^1,2, Mark Vangel¹, Ovidiu Andronesi^1,2, Isabel Arrillaga³, Deborah Forst³, Jayashree Kalpathy-Cramer ^1,2, Bruce Rosen^1,2, Tracy Batchelor³, Ramon Gilberto Gonzalez¹, and Eva-Maria Ratai^1,2

¹Radiology, Massachusetts General Hospital, Boston, MA, United States, ²Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, United States, ³Neurology, Massachusetts General Hospital, Boston, MA, United States, ⁴Radiology, Boston Children's Hospital, Boston, MA, United States

Our study examines the use of MR Spectroscopic Imaging to predict treatment response to anti-angiogenic therapy for recurrent glioblastoma patients. Our data demonstrated that early changes at 1-3 days, 4 weeks, and 6 weeks in Cho/NAA, Lac/nCr, and Lac/NAA can be predictive of 9-months survival outcomes in patients with recurrent glioblastoma treated with bevacizumab. Theses preliminary findings suggest that early changes in certain metabolic ratios can be useful markers for predicting therapeutic response to bevacizumab treatment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here